A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

Objective: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1, capecitabine plus lapatinib, and trastuzumab plus...

Full description

Bibliographic Details
Main Authors:	Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	Breast
Subjects:	Breast cancer Neoplasm metastasis Cost-effectiveness analysis Markov chains Taiwan
Online Access:	http://www.sciencedirect.com/science/article/pii/S096097761931104X

Similar Items

Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting
by: Vakaramoko Diaby, et al.
Published: (2020-04-01)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
by: Belal Firwana, et al.
Published: (2012-07-01)

Analysis of Surgically Treated Intraspinal Tumors in Southern Taiwan
by: Yu‐Feng Su, et al.
Published: (2007-11-01)

In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Alwin Jeyakumar, et al.
Published: (2012-01-01)

Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
by: Alwin Jeyakumar, et al.
Published: (2012-04-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
by: M. Calamac, et al.
Published: (2021-04-01)

Cost-effectiveness of amlodipine compared with valsartan in preventing stroke and myocardial infarction among hypertensive patients in Taiwan
by: Chan L, et al.
Published: (2016-05-01)

Méthode pour l’établissement d’une liste de médicaments remboursables dans le cadre du nouveau programme d’assurance-médicaments en Côte d’Ivoire
by: Diaby, Vakaramoko
Published: (2012)

Méthode pour l’établissement d’une liste de médicaments remboursables dans le cadre du nouveau programme d’assurance-médicaments en Côte d’Ivoire
by: Diaby, Vakaramoko
Published: (2012)

Impact économique de la Tibolone comparativement à l'hormonothérapie substitutive dans le contrôle des symptômes climatériques chez les femmes post-ménopausées
by: Diaby, Vakaramoko
Published: (2016)

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
by: G Norman, et al.
Published: (2011-05-01)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
by: Sawaki M
Published: (2014-04-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Metastatic cellular fibrous histiocytoma
by: Yi-Teng Tseng, et al.
Published: (2016-06-01)

Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era
by: Karam Irene, et al.
Published: (2011-12-01)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
by: Qiaoping Xu, et al.
Published: (2021-02-01)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
by: Han Y, et al.
Published: (2019-05-01)

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
by: Orlando Laura, et al.
Published: (2006-09-01)

Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
by: Andrea Fontana
Published: (2018-06-01)

Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
by: Zhang P, et al.
Published: (2020-06-01)

Population-based outcomes after brain radiotherapy in patients with brain metastases from breast cancer in the Pre-Trastuzumab and Trastuzumab eras
by: Karam Irene, et al.
Published: (2013-01-01)

Metastatic dermatosis in breast carcinoma on adjuvant trastuzumab: Is skin a sanctuary site in human epidermal growth factor receptor-2-amplified disease?
by: Amit Sehrawat, et al.
Published: (2018-01-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Gastrointestinal Metastatic Melanoma: The Key for Diagnosis
by: Daniela Filipa Soares Santos, et al.
Published: (2021-08-01)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
by: Ran R, et al.
Published: (2020-05-01)

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
by: Lin Shen
Published: (2018-12-01)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
by: Daphne Gschwantler-Kaulich, et al.
Published: (2017-01-01)

Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series
by: Vincenzo Di Lauro, et al.
Published: (2012-01-01)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019-10-01)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
by: Yue Hao, et al.
Published: (2019-01-01)

Health state utilities for metastatic breast cancer in Taiwan
by: Tzu-Chun Chou, et al.
Published: (2020-06-01)

Ocular involvement in metastatic and systemic malignancies is not rare
by: Purnima Rajkarnikar Sthapit, et al.
Published: (2021-08-01)

A significant response to a combination of trastuzumab and vinorelbine in HER2-negative metastatic breast cancer with HER2 V777L mutation
by: Lei L, et al.
Published: (2019-04-01)

A mathematical model of absorbing Markov chains to understand the routes of metastasis
by: David Hipólito Margarit, et al.
Published: (2016-08-01)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01)